← All trials
NCT05905055
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2023
- Primary completion
- Feb 28, 2025
- Completion date
- Feb 28, 2025
- First posted
- Jun 15, 2023
- Last posted
- Oct 26, 2023
- Enrollment
- 150
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Meiji Seika Pharma Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.